Home > Cellulaire therapie > Allogene stamceltransplantatie > Acute graft versus host disease (aGVHD) > IL-6 Siltuximab aGVHD

IL-6 Siltuximab aGVHD

A phase II study to assess the efficacy and tolerability of siltuximab in addition to standard of care tacrolimus and corticosteroids in first line treatment of grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract.

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 17-5-2025, 19:44